Dysregulated B Cell Expression of RANKL and OPG Correlates with Loss of Bone Mineral Density in HIV Infection

PLoS Pathogens

Volumn 10, Issue 11, 2014, Pages

  Titanji, Kehmia ^a   Vunnava, Aswani ^a   Sheth, Anandi N ^a   Delille, Cecile ^a   Lennox, Jeffrey L ^a   Sanford, Sara E ^a   Foster, Antonina ^a   Knezevic, Andrea ^b   Easley, Kirk A ^b   Weitzmann, M Neale ^a,c,d   Ofotokun, Ighovwerha ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TNFSF11 PROTEIN, HUMAN;

ADULT; ARTICLE; B LYMPHOCYTE; BONE DENSITOMETRY; BONE DENSITY; BONE MINERAL; BONE TURNOVER; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FRAGILITY FRACTURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; PROTEIN EXPRESSION; UPREGULATION; BIOLOGICAL MODEL; COMPLICATION; CROSS-SECTIONAL STUDY; METABOLISM; MIDDLE AGED; OSTEOPOROSIS; PATHOLOGY;

ADULT; B-LYMPHOCYTES; BONE DENSITY; CROSS-SECTIONAL STUDIES; CYTOKINES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NF-KAPPA B; OSTEOPOROSIS; OSTEOPROTEGERIN; RANK LIGAND;

EID: 84912124551     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004497     Document Type: Article

References (43)

1. Gandhi RT, Sax PE, Grinspoon SK, (2012) Metabolic and cardiovascular complications in HIV-infected patients: new challenges for a new age. J Infect Dis 205 Suppl 3S353–354.
2. Guaraldi G, Orlando G, Zona S, Menozzi M, Carli F, et al. (2011) Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 53: 1120–1126.
3. Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, et al. (2000) Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 14: F63–67.
4. Brown TT, Qaqish RB, (2006) Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 20: 2165–2174.
5. McComsey GA, Tebas P, Shane E, Yin MT, Overton ET, et al. (2010) Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clinical infectious diseases 51: 937–946.
6. Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J, (2003) Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 17: 1917–1923.
7. Grijsen ML, Vrouenraets SM, Steingrover R, Lips P, Reiss P, et al. (2010) High prevalence of reduced bone mineral density in primary HIV-1-infected men. Aids 24: 2233–2238.
8. Mondy K, Yarasheski K, Powderly WG, Whyte M, Claxton S, et al. (2003) Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 36: 482–490.
9. Schafer JJ, Manlangit K, Squires KE, (2013) Bone health and human immunodeficiency virus infection. Pharmacotherapy 33: 665–682.
10. Bolland MJ, Grey A, (2011) HIV and Low Bone Density: Responsible Party, or Guilty by Association? IBMS BoneKEy 8: 7–15.
11. Guaraldi G, Ventura P, Albuzza M, Orlando G, Bedini A, et al. (2001) Pathological fractures in AIDS patients with osteopenia and osteoporosis induced by antiretroviral therapy. AIDS 15: 137–138.
12. Triant VA, Brown TT, Lee H, Grinspoon SK, (2008) Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 93: 3499–3504.
13. Young B, Dao CN, Buchacz K, Baker R, Brooks JT (2011) Increased Rates of Bone Fracture among HIV-Infected Persons in the HIV Outpatient Study (HOPS) Compared with the US General Population, 2000–2006. Clin Infect Dis. 2011/03/15 ed.
14. Womack JA, Goulet JL, Gibert C, Brandt C, Chang CC, et al. (2011) Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One 6: e17217.
15. Prior J, Burdge D, Maan E, Milner R, Hankins C, et al. (2007) Fragility fractures and bone mineral density in HIV positive women: a case-control population-based study. Osteoporos Int 18: 1345–1353.
16. Guerri-Fernandez R, Vestergaard P, Carbonell C, Knobel H, Aviles FF, et al. (2013) HIV infection is strongly associated with hip fracture risk, independently of age, gender, and comorbidities: a population-based cohort study. J Bone Miner Res 28: 1259–1263.
17. Teitelbaum SL, (2000) Bone resorption by osteoclasts. Science 289: 1504–1508.
18. Khosla S, (2001) Minireview: the OPG/RANKL/RANK system. Endocrinology 142: 5050–5055.
19. Yun TJ, Chaudhary PM, Shu GL, Frazer JK, Ewings MK, et al. (1998) OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J Immunol 161: 6113–6121.
20. Toraldo G, Roggia C, Qian WP, Pacifici R, Weitzmann MN, (2003) IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells. Proc Natl Acad Sci U S A 100: 125–130.
21. Weitzmann MN, (2013) The Role of Inflammatory Cytokines, the RANKL/OPG Axis, and the Immunoskeletal Interface in Physiological Bone Turnover and Osteoporosis. Scientifica 2013: 1–29.
22. Weitzmann MN, Pacifici R, (2006) Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest 116: 1186–1194.
23. Moir S, Ho J, Malaspina A, Wang W, DiPoto AC, et al. (2008) Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med 205: 1797–1805.
24. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, et al. (2006) PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443: 350–354.
25. Vikulina T, Fan X, Yamaguchi M, Roser-Page S, Zayzafoon M, et al. (2010) Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats. Proc Natl Acad Sci U S A 107: 13848–13853.
26. Li Y, Toraldo G, Li A, Yang X, Zhang H, et al. (2007) B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood 109: 3839–3848.
27. Onal M, Xiong J, Chen X, Thostenson JD, Almeida M, et al. (2012) Receptor activator of nuclear factor kappaB ligand (RANKL) protein expression by B lymphocytes contributes to ovariectomy-induced bone loss. J Biol Chem 287: 29851–29860.
28. Kawai T, Matsuyama T, Hosokawa Y, Makihira S, Seki M, et al. (2006) B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am J Pathol 169: 987–998.
29. Moir S, Fauci AS, (2009) B cells in HIV infection and disease. Nat Rev Immunol 9: 235–245.
30. Titanji K, De Milito A, Cagigi A, Thorstensson R, Grutzmeier S, et al. (2006) Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. Blood 108: 1580–1587.
31. Manolagas SC, Jilka RL, (1995) Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 332: 305–311.
32. Shimizu Y, Sakai A, Menuki K, Mori T, Isse T, et al. (2011) Reduced bone formation in alcohol-induced osteopenia is associated with elevated p21 expression in bone marrow cells in aldehyde dehydrogenase 2-disrupted mice. Bone 48: 1075–1086.
33. Collin F, Duval X, Le Moing V, Piroth L, Al Kaied F, et al. (2009) Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. AIDS 23: 1021–1024.
34. Cotter AG, Sabin CA, Simelane S, Macken A, Kavanagh E, et al. (2014) Relative contribution of HIV infection, demographics and body mass index to bone mineral density. AIDS 28: 2051–2060.
35. Hui SL, Slemenda CW, Johnston CC, Jr (1988) Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 81: 1804–1809.
36. Arora S, Agrawal M, Sun L, Duffoo F, Zaidi M, et al. (2010) HIV and bone loss. Current osteoporosis reports 8: 219–226.
37. Gibellini D, Borderi M, De Crignis E, Cicola R, Vescini F, et al. (2007) RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naive HIV-1-positive men. J Med Virol 79: 1446–1454.
38. Dolan SE, Huang JS, Killilea KM, Sullivan MP, Aliabadi N, et al. (2004) Reduced bone density in HIV-infected women. Aids 18: 475–483.
39. Ueland T, Bollerslev J, Godang K, Muller F, Froland SS, et al. (2001) Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess–possible role in bone homeostasis. Eur J Endocrinol 145: 685–690.
40. Hwang JJ, Wei J, Abbara S, Grinspoon SK, Lo J, (2012) Receptor activator of nuclear factor-kappaB ligand (RANKL) and its relationship to coronary atherosclerosis in HIV patients. J Acquir Immune Defic Syndr 61: 359–363.
41. Brown TT, Chen Y, Currier JS, Ribaudo HJ, Rothenberg J, et al. (2013) Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr 63: 323–330.
42. Kanis JA, (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359: 1929–1936.
43. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, et al. (2003) Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 111: 1221–1230.